Loading stock data…
$6.58+0.30 (+4.78%)
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer.
NextCure, Inc. in the Healthcare sector is trading at $6.58 with a market capitalization of $30M. Wall Street consensus targets $20.00 (1 analysts), implying a +204.0% move over the next 12 months. The stock is currently 58% below its 52-week high of $15.74, remaining 20.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.02M↑ | -$10.11M↓ | -$9.76M↓ | -$8.95M↑ | -$27.29M |
| Net Income | -$14.89M↓ | -$9.80M↓ | -$9.44M↓ | -$8.62M↑ | -$26.81M |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that i...